Primary breast lymphoma
ICD-10 C84.7 · ICD-11 2A81.Y

Treatment of Primary Breast Lymphoma — CD20-Negative, Non-Hodgkin's Type, Stage IE or IIE

Clinical scenario
Non-Hodgkin's lymphoma pathological type CD20-negative Stage IE or IIE First-line protocol

This protocol covers primary breast lymphoma of non-Hodgkin's histological type in which tumor cells are CD20-negative, presenting at early localised or regionally-involved stage (IE or IIE). Because CD20 expression is absent, anti-CD20 therapy is not applicable — the treatment approach is tailored accordingly.

Treatment approach (partial overview)

Management follows a multimodal strategy. Systematic anthracycline-based chemotherapy forms the backbone, delivered over multiple cycles using a specific regimen. This is combined with radiotherapy and, where needed for a pathological diagnosis, limited surgery. The complete regimen, cycle count, radiation field and dose parameters, and surgical specifics are contained in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s12957-023-03007-8

All patients in this study received systematic chemotherapy after diagnosis; the protocols included the ABVD regimen (comprising doxorubicin, bleomycin, vinblastine, and dacarbazine) (4.5%) for Hodgkin's lymphoma and the CHOP (79.1%) or E-CHOP (16.4%) regimen for non-Hodgkin's lymphoma.

Multiple treatment approaches, including anthracycline-containing chemotherapy, radiotherapy, and limited surgery, are recommended for the initial treatment of patients with PBL.

Rituximab provided a new choice for CD20-positive PBL patients.

View source ↗